FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	DC	20549
vvasi ii iytori,	D.C.	20349

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number: 3235-028									
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Scanlan Sean F.						2. Issuer Name <b>and</b> Ticker or Trading Symbol TREACE MEDICAL CONCEPTS, INC. [TMCI]									5. Relationship of Rep (Check all applicable) Director Officer (give below)			10% Owr		
(Last) (First) (Middle)  C/O TREACE MEDICAL CONCEPTS, INC.  203 FORT WADE ROAD, SUITE 150					11	/10/20	)21				th/Day/Year)	SVP, Marketing								
(Street) PONTE (City)	VEDRA FI		32081 (Zip)		_	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indiv Line) X	ividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
Date				2. Transact Date (Month/Day		Execut (Year) if any		Deemed cution Date, y nth/Day/Year)		action (Instr.	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			d 5)	5. Amount of Securities Beneficially Owned Following Reported		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(A) or (D)	Price		Transac (Instr. 3	ction(s)			(111501.4)	
Common Stock 11/10				11/10/2	021	021			M <sup>(1)</sup>		25,000	A	\$1	.57	25	5,000		D		
Common Stock 11/10/2				021	)21			S <sup>(1)</sup>		24,560	D	\$21.5	254 <sup>(2)</sup>	4	440		D			
Common Stock 11/10/20				021	21			S <sup>(1)</sup>		440	D	\$22.1	\$22.1981 <sup>(3)</sup>		0		D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execution Date, if any			Transaction Code (Instr.				te Exer ation D th/Day/		7. Title and Amou of Securities Underlying Derivative Securi (Instr. 3 and 4)		D	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Owners Form: Direct (I or Indirect) (I) (Insti	Ownership	Beneficial Ownership ct (Instr. 4)	
						v	(A)	(D)	Date Exerc	cisable	Expiration Date	Title	Amo or Num of Shar	ber						
Stock Option (Right to Buy)	\$1.57	11/10/2021			M <sup>(1)</sup>			25,000	(	(4)	04/23/2029	Commor Stock	25,0	000	\$0	57,524	1	D		

## Explanation of Responses:

- 1. Transactions made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
- 2. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from \$21.14 to \$22.13 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 3. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from \$22.15 to \$22.26 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 4. The stock option is partially vested and will vest with respect to the remaining shares in equal annual installments, so that the options will be fully vested on April 23, 2023.

/s/ Lisa Taylor as Attorney-infact for Sean Scanlan 11/12/2021

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.